摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

植酸钠 | 17211-15-3

中文名称
植酸钠
中文别名
肌醇六磷酸钠;植酸钠盐水合物;植酸十二钠;植酸钠水合物;肌醇六(磷酸二氢酯)钠盐
英文名称
Sodium phytate
英文别名
dodecasodium;(2,3,4,5,6-pentaphosphonatooxycyclohexyl) phosphate
植酸钠化学式
CAS
17211-15-3;14306-25-3
化学式
C6H6Na12O24P6
mdl
——
分子量
923.82
InChiKey
KETSPIPODMGOEJ-UHFFFAOYSA-B
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    2.04[at 20℃]
  • 溶解度:
    在水中的溶解度为50mg/mL,清澈至微浑浊,无色至淡黄色
  • LogP:
    -8.465 (est)

计算性质

  • 辛醇/水分配系数(LogP):
    -46.67
  • 重原子数:
    48
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    435
  • 氢给体数:
    0
  • 氢受体数:
    24

SDS

SDS:5af58977f521b2c5d9a79a45ccee5971
查看

制备方法与用途

概述

植酸钠是一种有机钠盐,为白色吸湿性粉末,易溶于水。其水溶液具有较强的碱性。植酸钠既含有较多的钠离子,可以作为活性染料促染剂,又具有一定的碱性,可以作为活性染料固色剂。它广泛存在于谷类、豆类和油料作物中,在食品工业上可用作抗氧化剂、抑菌剂、护色剂、螯合剂和保鲜剂等。

在一定条件下,植酸钠易发生水解,生成肌醇五磷酸钠、肌醇四磷酸钠、肌醇三磷酸钠、肌醇二磷酸钠、肌醇磷酸钠和肌醇。其中,肌醇三磷酸具有细胞内信号转导的作用;而肌醇则具有抗癌、防止衰老的作用。植酸钠由于其较强的螯合能力,易于与钙、镁等金属离子结合形成螯合物,并且所形成的络合物稳定性强,在食品、医药和日化等行业中具有广泛的应用价值。

应用

植酸钠又称肌醇六磷酸钠,化学名称为Dodecasodium phytate或Myo-inositol hexakisphosphate。常温下呈白色粉末状,易溶于水。其母体植酸是一种广泛存在于植物种子、谷物、胚芽和米糠中的有机磷酸化合物。植酸及其钠盐具有较强的金属螯合能力,因其主要功能基团是六元环结构,含有24个氧原子、12个羟基及6个磷酸基,在与金属相遇时易于形成多个螯合环,并且形成的络合物稳定性强。因此,植酸及其钠盐在食品、医药和日化等行业具有广泛的应用价值。

制备

植酸钠的制备方法主要有两种:一是植酸与氢氧化钠中和反应;二是离子交换法。植物种子、谷物、胚芽和米糠是主要来源,可通过化学合成法、微生物发酵法或溶剂萃取法等提取。

生物活性

植酸钠(磷酸肌醇)在临床上可用作低钙剂及络合剂,用于去除微量重金属离子。它也是其他肌醇磷脂和焦磷酸盐的前体和储存库。

化学性质

纯白色颗粒结晶状物质,易溶于甲醇、乙醇、DMSO等有机溶剂。主要来源于米糠、植物胚芽及玉米。

用途

用于食品、化妆品、香皂以及罐头添加剂等。

反应信息

  • 作为反应物:
    描述:
    植酸钠吡啶吡啶 、 N,N-dicyclohexylcarbodiimide 作用下, 以 为溶剂, 反应 18.0h, 以to give thepentapyridinium Salt of Myo-inositol 1,6:2,3的产率得到1L-手性纤维醇
    参考文献:
    名称:
    Inositol pyrophosphates, and methods of use thereof
    摘要:
    本发明涉及化合物、其组合物和方法,能够将含有内部焦磷酸酯环的改性肌醇六磷酸(IHP)传递到哺乳动物细胞的细胞质中。在某些实施例中,本发明涉及化合物、其组合物和方法,通过将IHP传递到红细胞的细胞质中,增强哺乳动物红细胞传递氧气的能力。
    公开号:
    US20040014642A1
点击查看最新优质反应信息

文献信息

  • Inositoltriphosphate
    申请人:——
    公开号:US04777134A1
    公开(公告)日:1988-10-11
    An inositoltriphosphate (IP.sub.3) selected from the group consisting of D-myo-inositol-1.2.6-triphosphate, D-myo-inositol-1.2.5-triphosphate, L-myo-inositol-1.3.4-triphosphate and myo-inositol-1.2.3-triphosphate, a method for producing the same and a composition comprised of the same.
    一种肌醇三磷酸(IP.sub.3),所选自D-肌醇-1.2.6-三磷酸、D-肌醇-1.2.5-三磷酸、L-肌醇-1.3.4-三磷酸和肌醇-1.2.3-三磷酸组成的群组,以及生产该肌醇三磷酸的方法和包含该肌醇三磷酸的组合物。
  • Inositol triphosphates
    申请人:——
    公开号:US04851560A1
    公开(公告)日:1989-07-25
    The disclosure of the present invention is directed to an inositol triphosphate compound, useful as a pharmaceutical agent, having the structural formula ##STR1## where (a) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydrogen; (b) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydrogen; (c) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.11 are hydrogen; (d) three or R.sub.1, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen; (e) three of R.sub.1, R.sub.3, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydrogen; (f) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.11 are hydrogen; (g) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydrogen; or (h) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.9 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.10 and R.sub.12 are hydrogen.
    本发明的披露涉及一种肌醇三磷酸化合物,其具有以下结构式,可用作药物制剂:##STR1## 其中(a)R1、R3、R5、R7、R10和R11中的三个为羟基,其余三个为磷酸酯,R2、R4、R6、R8、R9和R12为氢;(b)R1、R3、R6、R7、R9和R12中的三个为羟基,其余三个为磷酸酯,R2、R4、R5、R8、R10和R11为氢;(c)R1、R3、R5、R8、R10和R12中的三个为羟基,其余三个为磷酸酯,R2、R4、R6、R7、R9和R11为氢;(d)R1、R4、R5、R8、R9和R12中的三个为羟基,其余三个为磷酸酯,R2、R3、R6、R7、R10和R11为氢;(e)R1、R3、R6、R8、R9和R12中的三个为羟基,其余三个为磷酸酯,R2、R4、R5、R7、R10和R11为氢;(f)R1、R3、R6、R7、R10和R12中的三个为羟基,其余三个为磷酸酯,R2、R4、R5、R8、R9和R11为氢;(g)R1、R3、R5、R8、R10和R11中的三个为羟基,其余三个为磷酸酯,R2、R4、R6、R7、R9和R12为氢;或(h)R1、R3、R5、R7、R9和R11中的三个为羟基,其余三个为磷酸酯,R2、R4、R6、R8、R10和R12为氢。
  • Methods and composition for mineralizing and fluoridating calcified
    申请人:American Dental Association Health Foundation
    公开号:US06000341A1
    公开(公告)日:1999-12-14
    This invention involves new compositions and methods of use and delivery of amorphous calcium compounds such as: amorphous calcium phosphate (ACP), amorphous calcium phosphate fluoride (ACPF), amorphous calcium carbonate phosphate (ACCP), amorphous calcium carbonate phosphate fluoride (ACCPF), and amorphous calcium fluoride (ACF) for use in remineralizing and fluoridating teeth. These amorphous compounds or solutions which form the amorphous compounds or calcium phosphate jelly which forms the amorphous compounds, when applied either onto or into dental tissue to prevent and/or repair dental weaknesses such as dental caries, exposed roots and dentin sensitivity. The compounds have the highest solubilities, fastest formation rates and fastest conversion rates (to apatite) among all the calcium phosphates under physiological conditions. Moreover, in the presence to fluoride the amorphous compound convert rapidly to fluoride containing apatite.
    本发明涉及新的组合物和使用方法以及输送无定形钙化合物,例如:无定形磷酸钙(ACP),无定形磷酸钙氟化物(ACPF),无定形碳酸钙磷酸盐(ACCP),无定形碳酸钙磷酸氟化物(ACCPF)和无定形氟化钙(ACF)用于牙齿的再矿化和氟化。这些无定形化合物或形成无定形化合物的溶液或形成无定形化合物的磷酸钙凝胶,当施加于或进入牙齿组织以预防和/或修复牙齿的弱点,例如龋齿,暴露的根和牙本质敏感。这些化合物在生理条件下具有最高的溶解度、最快的形成速率和最快的转化速率(到磷灰石)。此外,在氟化物存在的情况下,无定形化合物会迅速转化为含氟磷灰石。
  • INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF
    申请人:NICOLAU Yves Claude
    公开号:US20110281825A1
    公开(公告)日:2011-11-17
    The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphosphate (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.
    本发明包括化合物、其组合物和方法,能够将具有内部焦磷酸酯环的修饰肌醇六磷酸(IHP)输送到哺乳动物细胞的细胞质中。在某些实施例中,本发明涉及化合物、其组合物和方法,通过将IHP输送到红细胞的细胞质中,增强哺乳动物红细胞输送氧气的能力。
  • FEED SUPPLEMENT
    申请人:Isaksen Mai Faurschou
    公开号:US20120107296A1
    公开(公告)日:2012-05-03
    The present invention relates to a feed supplement comprising a phytase and a lipolytic enzyme, wherein said lipolytic enzyme has lipase activity at a pH in the range of about pH1.5 to about pH3.5.
    本发明涉及一种饲料补充剂,包括植酸酶和脂肪水解酶,其中所述的脂肪水解酶在pH1.5到pH3.5范围内具有脂肪酶活性。
查看更多